10/ 533,931

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 27	JUL 16	CAplus enhanced with French and German abstracts
NEWS 28	JUL 18	CA/CAplus patent coverage enhanced
NEWS 29	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

10/ 533,931

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:26:24 ON 26 JUL 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:26:31 ON 26 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8
DICTIONARY FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10533931.str





chain nodes :
11 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19 20
chain bonds :
7-11 11-12 21-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 16-18 17-20 18-19 19-20
exact/norm bonds :
7-11 11-12 16-18 17-20 18-19 19-20 21-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17

G1:C,O,S,N,SO2,[*1]

Hydrogen count :
9:= exact 1
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d L1

10/ 533,931

L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N,SO2,[@1]

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 17:26:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        2 TO ITERATE

100.0% PROCESSED        2 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            2 TO      124
PROJECTED ANSWERS:               2 TO      124

L2            2 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 17:27:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       60 TO ITERATE

100.0% PROCESSED       60 ITERATIONS                                60 ANSWERS
SEARCH TIME: 00.00.01

L3           60 SEA SSS FUL L1

=> file zcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     172.10     172.31

FILE 'ZCAPLUS' ENTERED AT 17:27:08 ON 26 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

10/ 533,931

FILE COVERS 1907 - 26 Jul 2007 VOL 147 ISS 5
FILE LAST UPDATED: 25 Jul 2007 (20070725/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L4           4 L3

=> d his

     (FILE 'HOME' ENTERED AT 17:26:24 ON 26 JUL 2007)

     FILE 'REGISTRY' ENTERED AT 17:26:31 ON 26 JUL 2007
L1              STRUCTURE UPLOADED
L2            2 S L1
L3           60 S L1 FUL

     FILE 'ZCAPLUS' ENTERED AT 17:27:08 ON 26 JUL 2007
L4            4 S L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L4   ANSWER 1 OF 4  ZCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2004:995977  ZCAPLUS
DOCUMENT NUMBER:         141:420417
TITLE:                   Therapeutic agents comprising an anti-angiogenic agent
                         in combination with an Src inhibitor for use in
                         normotensive treatment of angiogenesis
INVENTOR(S):             Curwen, Jon Owen; Wedge, Stephen Robert
PATENT ASSIGNEE(S):      Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE:                  PCT Int. Appl., 111 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     WO 2004098604        A1    20041118    WO 2004-GB1939         20040504
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
```

	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2004237132	A1	20041118	AU 2004-237132	20040504
CA	2519930	A1	20041118	CA 2004-2519930	20040504
EP	1620104	A1	20060201	EP 2004-731049	20040504
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR	2004009742	A	20060509	BR 2004-9742	20040504
CN	1784232	A	20060607	CN 2004-80012089	20040504
JP	2006525304	T	20061109	JP 2006-506222	20040504
NO	2005004411	A	20051130	NO 2005-4411	20050923
US	2006223815	A1	20061005	US 2005-555389	20051103
MX	2005PA11858	A	20060217	MX 2005-PA11858	20051104
PRIORITY APPLN. INFO.:				GB 2003-10401 A	20030507
				WO 2004-GB1939 W	20040504

GI



I



II

AB The invention relates to the use of an anti-angiogenic agent, such as I (preparation given), in combination with an inhibitor of the Src family of non-receptor tyrosine kinases, such as the II (prepns. according to a previous patent given), in the manufacture of a medicament for use in the substantially normotensive treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis. The invention

provides for the Src kinase inhibitor to be administered in an amount effective to counteract substantially the hypertension induced by the anti-angiogenic agent. Thus, 7-(2-chloroethoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline was coupled with 1-acetylpiperazine using KI in DMA to give I. The diastolic blood pressure profile of rats over a 24 h period after administration of a combination of 1.5 mg/kg of I and 25 mg/kg of II demonstrated that the contrasting blood pressure effects of the antiangiogenic agent and the Src kinase inhibitor were substantially counterbalanced.

IT 692054-06-1, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-5-isopropoxyquinazoline
692054-28-7, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline
692054-33-4 692054-44-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Src kinase inhibitor; therapeutic agents comprising an anti-angiogenic agent in combination with an Src inhibitor for use in normotensive treatment of angiogenesis)

RN 692054-06-1 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-28-7 ZCAPLUS

CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-33-4 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692054-44-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:857372 ZCAPLUS
DOCUMENT NUMBER: 141:350196
TITLE: Preparation of quinazoline derivatives as selective Src kinase inhibitors
INVENTOR(S): Curwen, Jon Owen
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087120	A2	20041014	WO 2004-GB1286	20040323

WO 2004087120 A3 20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: GB 2003-7333 A 20030329

AB The invention relates to the use of quinazoline derivative as a Src kinase inhibitor in the production of a medicament for use in the prophylaxis or treatment of hypertension. More particularly, the invention concerns the anti-hypertensive use of a selective Src kinase inhibitor that possess less potent VEGF receptor tyrosine kinase inhibitory properties. The invention also relates to a combination product comprising a Src kinase inhibitor and one or more further anti-hypertensive agents and to the use of Src kinase inhibitors as primary regulators of cardiovascular disease and in the prevention of stroke. For example, 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxyquinazoline administered to rats at 25 mg/kg p.o. on day 1 showed hypotensive effect of 25 mmHg on day 2.

IT 692053-03-5P, 4-(5-Chloro-2,3-methylenedioxypyridin-4-ylamino)-7-(3-chloropropoxy)-6-methoxyquinazoline
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)

RN 692053-03-5 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-6-methoxy- (9CI) (CA INDEX NAME)



IT 692054-44-7, 4-(5-Chloro-2,3-methylenedioxypyrid-4-ylamino)-7-[2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy]-5-isopropoxyquinazoline
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)

RN 692054-44-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 692053-13-7P, 4-(5-Chloro-2,3-methylenedioxypyridin-4-ylamino)-6-methoxy-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline
692054-06-1P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyridin-4-ylamino)-5-isopropoxyquinazoline
692054-11-8P, 4-(5-Chloro-2,3-methylenedioxypyridin-4-ylamino)-6-methoxy-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]quinazoline
692054-16-3P, 4-(5-Chloro-2,3-methylenedioxypyridin-4-ylamino)-6-Methoxy-7-[3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy]quinazoline
692054-22-1P, 4-(5-Chloro-2,3-methylenedioxypyridin-4-ylamino)-6-methoxy-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]quinazoline
692054-28-7P, 4-(5-Chloro-2,3-methylenedioxypyridin-4-ylamino)-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-5-(tetrahydropyran-4-yloxy)quinazoline
692054-33-4P, 4-(5-Chloro-2,3-methylenedioxypyridin-4-ylamino)-5-(tetrahydropyran-4-yloxy)-7-[2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy]quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)

RN 692053-13-7 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 692054-06-1 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-11-8 ZCAPLUS
CN Piperazine, 1-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 692054-16-3 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 692054-22-1 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-28-7 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-(9CI) (CA INDEX NAME)



RN 692054-33-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 692053-08-0P, 7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyridin-4-ylamino)-6-methoxyquinazoline 692053-18-2P, 7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyridin-4-ylamino)-5-tetrahydropyran-4-yloxyquinazoline 692053-23-9P,

7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyridin-4-ylamino)-5-isopropoxyquinazoline
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(reactant; preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)

RN 692053-08-0 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-18-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692053-23-9 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:430753 ZCAPLUS
DOCUMENT NUMBER: 141:1220
TITLE: Preparation of quinazolines as Src family non-receptor tyrosine kinase inhibitors for use in combination therapy with gemcitabine for treatment and prophylaxis of pancreatic cancer
INVENTOR(S): Barge, Alan
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043472	A1	20040527	WO 2003-GB4787	20031107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2504666	A1	20040527	CA 2003-2504666	20031107
AU 2003279456	A1	20040603	AU 2003-279456	20031107
AU 2003279456	B2	20070517		
EP 1562612	A1	20050817	EP 2003-772404	20031107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016170	A	20050927	BR 2003-16170	20031107
CN 1711094	A	20051221	CN 2003-80103138	20031107
JP 2006508953	T	20060316	JP 2004-550784	20031107
NO 2005002312	A	20050606	NO 2005-2312	20050511
US 2006142297	A1	20060629	US 2005-534721	20051020
PRIORITY APPLN. INFO.:			GB 2002-26434 A	20021113
			WO 2003-GB4787 W	20031107

GI



I

AB The invention concerns a combination comprising an inhibitor of Src kinase and the cytotoxic agent, gemcitabine, a pharmaceutical composition comprising such a combination, and its use in the treatment or prophylaxis of cancer, particularly of pancreatic cancer. Examples include prepns. for anilino- and (pyridylamino)quinazoline Src inhibitors (no Markush structure given) and bioassays demonstrating the synergistic effect of treating pancreatic cancer with a quinazoline Src inhibitor in combination with gemcitabine. For instance, 4-amino-5-chloro-2,3-methylenedioxypyridine was coupled with 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline (preparation of reactants given) in the presence of sodium hexamethyldisilazane in THF to afford the (pyridylamino)quinazoline I. Nude mice were injected with pancreatic tumor cells derived from the COLO 357 human pancreatic cancer cell line and treated with gemcitabine, the Src inhibitor, 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline, or a combination of the two. Evaluation for tumor growth and incidence of liver metastases showed that, compared with the weight of control tumors, tumor growth in animals treated with the combination was much reduced (1359 mg and 124 mg, resp.) to a level well below that achievable on the dosing of either gemcitabine or the Src inhibitor alone. In addition, there was no liver metastasis in the animals treated with the combination, whereas liver metastasis was present in 1/5 of the animals treated with gemcitabine alone.

IT 692053-03-5P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-(3-chloropropoxy)-6-methoxyquinazoline 692053-08-0P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-6-methoxyquinazoline 692053-18-2P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-23-9P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-5-isopropoxyquinazoline 692053-29-5P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-6-(2-chloroethoxy)-7-methoxyquinazoline 692053-34-2P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-6-(3-chloropropoxy)-7-methoxyquinazoline 692053-39-7P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-(3-chloropropoxy)-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-44-4P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-[(2,4-dimethoxybenzyl)oxy]-5-isopropoxyquinazoline 692053-55-7P, 7-(3-Chloropropoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-5-isopropoxyquinazoline 692053-59-1P, 7-(3-Chloropropoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692053-88-6P, 7-(N-tert-Butoxycarbonylpiperidin-4-ylmethoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-6-methoxyquinazoline 692053-94-4P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-6-methoxy-7-[(piperidin-4-yl)methoxy]quinazoline 692055-28-0P, 5-Isopropoxy-7-[2-(piperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antitumor agent; preparation of quinazoline-containing Src inhibitors for use
in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)

RN 692053-03-5 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-08-0 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-18-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692053-23-9 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 692053-29-5 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-(2-chloroethoxy)-7-methoxy- (9CI) (CA INDEX NAME)



RN 692053-34-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-(3-chloropropoxy)-7-methoxy- (9CI) (CA INDEX NAME)



RN 692053-39-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692053-44-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 692053-55-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 692053-59-1 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)- (9CI) (CA INDEX NAME)



RN 692053-88-6 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 692053-94-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 692055-28-0 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)



IT 692053-13-7P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-6-methoxy-7-[3-[4-(prop-2-ynyl)piperazin-1-yl]propoxy]quinazoline 692053-49-9P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-hydroxy-5-isopropoxyquinazoline 692053-63-7P, 7-(2-Chloroethoxy)-4-[(2,3-methylenedioxypyridin-4-yl)amino]-6-methoxyquinazoline 692053-68-2P, 7-(3-Chloropropoxy)-4-[(2,3-methylenedioxypyridin-4-yl)amino]-6-methoxyquinazoline 692053-72-8P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(2,3-methylenedioxypyridin-4-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-76-2P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(2,3-methylenedioxypyridin-4-yl)amino]-5-isopropoxyquinazoline 692053-82-0P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-[2-[4-(2-dimethylaminoacetyl)piperazin-1-yl]ethoxy]-5-isopropoxyquinazoline 692054-00-5P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-[[1-(2-dimethylaminoacetyl)piperidin-4-yl]methoxy]-6-methoxyquinazoline 692054-06-1P, 5-Isopropoxy-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-11-8P, 6-Methoxy-7-[3-(4-isobutyrylpiperazin-1-yl)propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-16-3P, 6-Methoxy-7-[3-[4-(2,2,2-trifluoroethyl)piperazin-1-yl]propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-22-1P, 6-Methoxy-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-28-7P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-33-4P 692054-44-7P 692054-49-2P, 6-[2-(Morpholino)ethoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-55-0P, 6-[2-(4-Methylpiperazin-1-yl)ethoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-60-7P, 6-[2-(Pyrrolidin-1-yl)ethoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-66-3P, 6-[2-(4-Acetylpiperazin-1-yl)ethoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-72-1P 692054-77-6P, 6-[3-(Pyrrolidin-1-yl)propoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-83-4P, 6-[3-(Morpholino)propoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-88-9P, 6-[3-(4-Acetylpiperazin-1-yl)propoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-94-7P, 6-[3-(4-Methylpiperazin-1-yl)propoxy]-7-methoxy-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-00-8P 692055-04-2P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-10-0P, 5-[(Tetrahydropyran-4-yl)oxy]-

7-[2-(morpholino)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-16-6P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[3-(morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-22-4P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[3-[4-(prop-2-ynyl)piperazin-1-yl]propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-34-8P, 5-Isopropoxy-7-[2-[4-(2-hydroxyethyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-41-7P, 5-Isopropoxy-7-[2-(pyrrolidin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-46-2P, 5-Isopropoxy-7-[2-(piperidino)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-53-1P, 5-Isopropoxy-7-[2-(morpholino)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-59-7P, 5-Isopropoxy-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-66-6P 692055-76-8P, 5-Isopropoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-83-7P, 5-Isopropoxy-7-[3-(morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-88-2P, 7-[3-(Morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-94-0P, 7-[3-(4-Acetylpiperazin-1-yl)propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692056-00-1P, 6-Methoxy-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692056-04-5P, 6-Methoxy-7-[3-[4-(prop-2-ynyl)piperazin-1-yl]propoxy]-4-[(2,3-methylenedioxypyridin-4-yl)amino]quinazoline 694439-00-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor agent; preparation of quinazoline-containing Src inhibitors for use
in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)

RN 692053-13-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 692053-49-9 ZCAPLUS
CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 692053-63-7 ZCAPLUS
CN 4-Quinazolinamine, 7-(2-chloroethoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-68-2 ZCAPLUS
CN 4-Quinazolinamine, 7-(3-chloropropoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-72-8 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692053-76-2 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692053-82-0 ZCAPLUS
CN Piperazine, 1-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-4-[(dimethylamino)acetyl]- (9CI) (CA INDEX NAME)



RN 692054-00-5 ZCAPLUS
CN Piperidine, 4-[[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-[(dimethylamino)acetyl]- (9CI) (CA INDEX NAME)



RN 692054-06-1 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-11-8 ZCAPLUS
CN Piperazine, 1-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 692054-16-3 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 692054-22-1 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-28-7 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-33-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692054-44-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692054-49-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-55-0 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-60-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-66-3 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-methoxy-6-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-72-1 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692054-77-6 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692054-83-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692054-88-9 ZCAPLUS
CN Piperazine, 1-acetyl-4-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-methoxy-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 692054-94-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692055-00-8 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]propoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692055-04-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692055-10-0 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-(4-morpholinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692055-16-6 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692055-22-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692055-34-8 ZCAPLUS
CN 1-Piperazineethanol, 4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692055-41-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-46-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-53-1 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-59-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-66-6 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-[2-[(3R,4S)-3,4-dimethoxy-1-pyrrolidinyl]ethoxy]-5-(1-methylethoxy)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692055-76-8 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-83-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692055-88-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692055-94-0 ZCAPLUS
CN Piperazine, 1-acetyl-4-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 692056-00-1 ZCAPLUS
CN 4-Quinazolinamine, N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692056-04-5 ZCAPLUS
CN 4-Quinazolinamine, N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 694439-00-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-[2-[(4aR,7aS)-hexahydro-6H-1,4-dioxino[2,3-c]pyrrol-6-yl]ethoxy]-5-(1-methylethoxy)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 692060-97-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazoline-containing Src inhibitors for use in
synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)
RN 692060-97-2 ZCAPLUS
CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 692053-49-9
CMF C17 H15 Cl N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 692060-84-7, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 694439-05-9, 7-(2-Chloroethoxy)-4-[(2,3-methylenedioxypyridin-4-yl)amino]quinazoline 694439-06-0, 7-(3-Chloropropoxy)-4-[(2,3-methylenedioxypyridin-4-yl)amino]quinazoline
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazoline-containing Src inhibitors for use in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)

RN 692060-84-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)- (9CI) (CA INDEX NAME)



RN 694439-05-9 ZCAPLUS
CN 4-Quinazolinamine, 7-(2-chloroethoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl- (9CI) (CA INDEX NAME)



RN 694439-06-0 ZCAPLUS
CN 4-Quinazolinamine, 7-(3-chloropropoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:414727 ZCAPLUS
DOCUMENT NUMBER: 140:423698
TITLE: Preparation of quinazoline derivatives as c-Src tyrosine kinase inhibitors
INVENTOR(S): Ple, Patrick
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041829	A1	20040521	WO 2003-GB4703	20031029

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA	2503371	A1	20040521	CA	2003-2503371	20031029
AU	2003278383	A1	20040607	AU	2003-278383	20031029
AU	2003278383	B2	20070614			
EP	1562955	A1	20050817	EP	2003-769689	20031029
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR	2003015756	A	20050906	BR	2003-15756	20031029
CN	1735617	A	20060215	CN	2003-80108194	20031029
JP	2006506463	T	20060223	JP	2005-502127	20031029
IN	2005DN01534	A	20061229	IN	2005-DN1534	20050415
NO	2005001900	A	20050601	NO	2005-1900	20050419
ZA	2005003337	A	20060726	ZA	2005-3337	20050425
MX	2005PA04858	A	20050722	MX	2005-PA4858	20050504
US	2006122199	A1	20060608	US	2005-533931	20050504
PRIORITY APPLN. INFO.:				EP	2002-292736 A	20021104
				EP	2003-290900 A	20030410
				WO	2003-GB4703 W	20031029

OTHER SOURCE(S): MARPAT 140:423698
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 = halo, CF3, cyano, isocyano, NO3, OH, SH, amino, formyl, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, etc.; Z = O, SO, SO2, N(R2)2, or C(R2)2; R2 = H or alkyl; m = 0-3; R3 = halo, CF3, CN, NO2, OH, amino, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, etc.; n =0-3] were prepared as c-Src tyrosine kinase inhibitors in the containment and/or treatment of solid tumor disease. For example, reaction of 4-amino-5-chloro-2,3-methylenedioxypyridine(preparation given) and 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline (preparation given) yielded compound II.

IT 692053-03-5P 692053-18-2P 692053-23-9P
692053-29-5P 692053-34-2P 692053-39-7P
692053-44-4P 692053-49-9P 692053-55-7P
692053-59-1P 692053-63-7P 692053-68-2P
692053-94-4P 692055-28-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)

RN 692053-03-5 ZCAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-18-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692053-23-9 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 692053-29-5 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-(2-chloroethoxy)-7-methoxy- (9CI) (CA INDEX NAME)



RN 692053-34-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-(3-chloropropoxy)-7-methoxy- (9CI) (CA INDEX NAME)



RN 692053-39-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692053-44-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 692053-49-9 ZCAPLUS
CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 692053-55-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 692053-59-1 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)- (9CI) (CA INDEX NAME)



RN 692053-63-7 ZCAPLUS
CN 4-Quinazolinamine, 7-(2-chloroethoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-68-2 ZCAPLUS
CN 4-Quinazolinamine, 7-(3-chloropropoxy)-N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-94-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-(4-piperidinylmethoxy)- (9CI) (CA INDEX NAME)



RN 692055-28-0 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)



IT 692053-08-0P 692053-13-7P 692053-72-8P
692053-76-2P 692053-82-0P 692053-88-6P
692054-00-5P 692054-06-1P 692054-11-8P
692054-16-3P 692054-22-1P 692054-28-7P
692054-33-4P 692054-44-7P 692054-49-2P
692054-55-0P 692054-60-7P 692054-66-3P
692054-72-1P 692054-77-6P 692054-83-4P
692054-88-9P 692054-94-7P 692055-00-8P
692055-04-2P 692055-10-0P 692055-16-6P
692055-22-4P 692055-34-8P 692055-41-7P
692055-46-2P 692055-53-1P 692055-59-7P
692055-66-6P 692055-76-8P 692055-83-7P
692055-88-2P 692055-94-0P 692056-00-1P
692056-04-5P 693272-25-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)
RN 692053-08-0 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-6-methoxy- (9CI) (CA INDEX NAME)



RN 692053-13-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 692053-72-8 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692053-76-2 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692053-82-0 ZCAPLUS
CN Piperazine, 1-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-4-[(dimethylamino)acetyl]- (9CI) (CA INDEX NAME)



RN 692053-88-6 ZCAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 692054-00-5 ZCAPLUS
CN Piperidine, 4-[[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-[(dimethylamino)acetyl]- (9CI) (CA INDEX NAME)



RN 692054-06-1 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-11-8 ZCAPLUS
CN Piperazine, 1-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-6-methoxy-7-quinazolinyl]oxy]propyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 692054-16-3 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[3-[4-(2,2,2-trifluoroethyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 692054-22-1 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-28-7 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-33-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692054-44-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692054-49-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-55-0 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-60-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692054-66-3 ZCAPLUS
CN Piperazine, 1-acetyl-4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-methoxy-6-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692054-72-1 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692054-77-6 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(1-pyrrolidinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692054-83-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692054-88-9 ZCAPLUS
CN Piperazine, 1-acetyl-4-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-methoxy-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 692054-94-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-(4-methyl-1-piperazinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692055-00-8 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-methoxy-6-[3-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]propoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692055-04-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692055-10-0 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-(4-morpholinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692055-16-6 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692055-22-4 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (9CI) (CA INDEX NAME)



RN 692055-34-8 ZCAPLUS
CN 1-Piperazineethanol, 4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 692055-41-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-46-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-53-1 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-59-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-66-6 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-6-[2-[(3R,4S)-3,4-dimethoxy-1-pyrrolidinyl]ethoxy]-5-(1-methylethoxy)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 692055-76-8 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 692055-83-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692055-88-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 692055-94-0 ZCAPLUS
CN Piperazine, 1-acetyl-4-[3-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 692056-00-1 ZCAPLUS
CN 4-Quinazolinamine, N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy-7-[2-[4-(2-propynyl)-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 692056-04-5 ZCAPLUS
CN 4-Quinazolinamine, N-1,3-dioxolo[4,5-b]pyridin-7-yl-6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]- (9CI) (CA INDEX NAME)



RN 693272-25-2 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-6-[2-[(3aR,6aS)-tetrahydro-2-methyl-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 692060-84-7 692060-97-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)
RN 692060-84-7 ZCAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)- (9CI) (CA INDEX NAME)



RN 692060-97-2 ZCAPLUS
CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

10/ 533,931

CM 1

CRN 692053-49-9
CMF C17 H15 Cl N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



=> d his

(FILE 'HOME' ENTERED AT 17:26:24 ON 26 JUL 2007)

FILE 'REGISTRY' ENTERED AT 17:26:31 ON 26 JUL 2007
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 60 S L1 FUL

FILE 'ZCAPLUS' ENTERED AT 17:27:08 ON 26 JUL 2007
L4 4 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.14	193.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

STN INTERNATIONAL LOGOFF AT 17:27:51 ON 26 JUL 2007